Despite positive clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant opposition from pharmacy benefit managers. The companies are often https://brendapcxi216453.daneblogger.com/40660669/copyright-s-drug-faces-is-dealing-with-pbm-hurdles-a-review-at-reimbursement-disputes